Direct evidence that lactogenic hormones induce homodimerization of membrane-anchored prolactin receptor in intact Nb2-11C rat lymphoma cells  by Sakal, Edna et al.
FEBS 18729 FEBS Letters 410 (1997) 289-292 
Direct evidence that lactogenic hormones induce homodimerization 
of membrane-anchored prolactin receptor in intact Nb2-llC rat 
lymphoma cells 
Edna Sakal, Gerard Elberg, Arieh Gertler* 
Institute of Biochemistry, Food Science and Nutrition, Faculty of Agriculture, The Hebrew University of Jerusalem, 
P. O. Box 12, Rehovot 76100, Israel 
Received 13 March 1997; revised version received 30 April 1997 
Abstract The ability of full-size prolactin receptor (PRLR) 
from Nb2 rat lymphoma cell line to undergo lactogenic hormone-
induced dimerization in intact cells or in a partially purified 
microsomal fraction was tested. The stoichiometry of ovine 
placental lactogen (oPL) binding to PRLR was documented by 
SDS-PAGE of the covalently cross-linked complexes between 
|1 2 5I]oPL and intact N b 2 - l l C cells. The molecular masses of the 
specific bands were 82 and 141 kDa, corresponding to 
PRLR:oPL and (PRLR)2 :oPL complexes. These results provide 
direct evidence for the occurrence of hormone-induced receptor 
dimerization in intact cells. Gel-filtration studies revealed that 
under non-denaturing conditions, the purified receptor forms 
high-molecular-mass aggregates (190 and 540 kDa) composed of 
receptor dimers and oligomers. Since this aggregation was not 
dependent on the presence of lactogenic hormone, it is possible 
that the receptor in the intact cells may already exist as a non-
covalent dimer or oligomer and that hormone-induced dimeriza-
tion stabilizes the complex or changes its conformation. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Hormone-induced sequential receptor dimerization has 
been proposed as an initial step in the action of human 
growth hormone (hGH) [1]. This suggestion was based on 
chemical and gel-filtration studies [1], on crystallization stud-
ies of the 2:1 complex between h G H receptor extracellular 
domain (hGHR-ECD) and h G H [2], and on indirect experi-
ments with intact hGH-responsive cells [3]. To elucidate 
whether the same mechanism also applies to prolactin 
(PRL) action, we prepared P R L R - E C D s from several species 
and studied their interaction with PRL, h G H , and other lac-
togenic hormones [4-7]. In contrast to h G H R - E C D , the in-
teraction of P R L R - E C D with lactogenic hormones yielded, in 
most cases, only a 1:1 complex. Structural 3-dimensional 
studies of the h G H : h P R L R - E C D complex showed also 1:1 
stoichiometry [8]. Only lately, via real-time kinetics studies 
with a Biacore apparatus , have we been able to provide evi-
dence that, in all cases, lactogenic hormones actually induced 
P R L R - E C D dimerization [9]. The 2:1 P R L R - E C D : h o r m o n e 
complex was, however, extremely unstable due to the high k0s 
constant, and underwent rapid dissociation to the 1:1 form. 
Although a few years ago we presented an indirect evidence of 
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receptor dimerization being an initial step in hormone-in-
duced signal transduction in the lactogenic hormone-respon-
sive rat lymphoma N b 2 - l l C cell line [10], direct documenta-
tion of full-size membrane-embedded P R L R undergoing 
lactogenic hormone-induced dimerization was lacking. Such 
evidence is presented here. 
2. Materials and methods 
2.1. Materials 
Ovine (o) PL was prepared by us as described previously [11] and 
hGH was a gift from Biotechnology General (Rehovot, Israel). Dis-
uccimidyl suberate (DSS) was from Pierce (Rockford, 1L, USA). Mo-
lecular-mass markers for SDS-PAGE were from Bio-Rad (Hercules, 
CA, USA). All other reagents were purchased from Sigma (St. Louis, 
MO, USA). 
2.2. Nb2-lymphoma cell proliferation 
Nb2-llC lymphoma cell culture and synchronization procedure 
were carried out as described previously [12]. 
2.3. Covalent cross-linking of [125IJoPL to Nb2-llC cells 
Synchronized Nb2-llC cells were centrifuged and suspended at 107 
cells/ml in PBS/0.1% (w/v) BSA. To 400 ul of cells in an Eppendorf 
tube, 50 ul of [125I]oPL (500 000 cpm, 6.2 ng) were added and the cells 
were incubated at 37°C for 30 min in the presence or absence of 40 ug 
unlabeled oPL. Freshly prepared DSS (0.25 M in dimethyl sulfoxide) 
was then added to a final concentration of 0.5 mM and the incubation 
was continued for an additional 30 min at room temperature. The 
reaction was stopped by adding 50 ul of 1 M glycine. The cells were 
pelleted (13000Xg, 1 min) at 4°C and washed 3 times in cold PBS. 
The cell pellet was lysed in 50 ul of lysis solution containing 1% (v/v) 
Triton X-100 and 1 uM PhMeS02F at 4°C for 20 min. Then 12 ul of 
5 X SDS-PAGE sample buffer was added, the tubes were boiled for 
5 min, centrifuged at 13000Xg for 5 min and separated by SDS-
PAGE on tricine gels [13]. The gels were fixed, dried and autoradio-
graphed at —70°C using Kodak XAR-5 film. Band density was de-
termined by image processing scanner. 
2.4. Preparation of a solubilized microsomal fraction from Nb2 -11C 
cells 
Synchronized Nb2-llC cells (1010 cells) were homogenized with 
Polytron (3 X 30 s at maximal speed in 4°C) in 250 ml of 25 mM 
HEPES-NaOH (pH 7.5) buffer containing 1 mM PhMeS02F, 50 
uM chloroquine, 0.01% (w/v) pepstatin 0.02%> (w/v) soybean trypsin 
inhibitor (SBTI), 0.01% (w/v) leupeptin, 1 mM ZnCl2, 1 mM EDTA 
and 1 mM EGTA. The homogenate was spun for 20 min at 600 Xg 
and the microsomal fraction was recovered by subsequent centrifuga-
tion at 150 000 X g for 1 h. The precipitate was suspended in 20 ml of 
25 mM HEPES-NaOH buffer, pH 7.5, containing 10 mM MgCl2, 
0.01% leupeptin, 1 mM PhMeS02F, 20 uM chloroquine and 0.01% 
soybean trypsin inhibitor, and solubilized with 1% Triton X-100, by 
stirring for 30 min at room temperature. Insolubilized material was 
removed by centrifugation at 150000Xg for 1 h and the soluble 
fraction was stored at —20°C until use. 
2.5. Gel filtration 
Aliquots (200 ul) of solubilized microsomal fraction (2.5 mg pro-
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tein/ml) or complex formed by an overnight pre-incubation of 
[125I]hGH (50X104 cpm/tube) with the solubilized microsomal frac-
tion in absence or present of 2 u.g hGH/tube were chromatographed at 
room temperature on a Superose 12 column (1 X30 cm) (Pharmacia, 
Uppsala, Sweden) equilibrated with 50 mM phosphate buffer, pH 7.4, 
containing 150 mM NaCl and 0.1% Triton X-100. The column was 
eluted with the same buffer at 0.5 ml/min. Fractions of 0.25 ml were 
collected during chromatography of the [125I]hGH:soluble receptor 
complex and counted on a y-counter. Gel nitration of the solubilized 
microsomal fraction was performed in an identical manner, except 
that 0.1 ml (in triplicates) of each 0.5 ml fraction collected was sub-
jected to radioreceptor assay. Each gel nitration experiments was per-
formed twice. 
2.6. Radioreceptor assay 
Binding of [125I]hGH (5 X 104 cpm/tube) to 100 ul aliquots of frac-
tions collected by gel filtration of the solubilized microsomal fraction 
was assayed, in triplicates in 25 mM HEPES buffer, pH 7.5, supple-
mented with 10 mM MgCl2, 0.5 mM PhMeS02F, 0.1% Triton X-100 
and 0.1% BSA. Non-specific binding was determined in the presence 
of unlabeled hGH (2 (ig/tube). The tubes were incubated for 14-16 h 
at 24°C. Following incubation, 500 JJ.1 of 25% polyethylenglycol sol-
ution was added to the reaction mixture. The tubes were centrifuged, 
the supernatant aspirated and the precipitate counted on a y-counter. 
Specific binding was calculated as % of total hGH counts. Radio-
iodination of hGH and oPL was carried out in the presence of chlor-
amine T and 1 mCi Na[125I], as described previously [14]. 
3. Results 
3.1. Determination of the stoichiometry of the full-size 
PRLR.hGH complex by gel filtration 
The first set of experiments was performed using solubilized 
microsomal fraction prepared from Nb2 cells synchronized in 
the absence of lactogenic hormones. Two types of experiments 
were performed. In the first experiment, molecular masses of 
the solubilized PRLR:[125I]hGH complex (Fig. 1A) and in the 
second free receptors in the solubilized fraction (Fig. IB) were 
separated by gel filtration on a Superose 12 column and sub-
sequently identified by their capacity to bind iodinated 
[125I]hGH. The iodinated ligand was found in four of the 
eluted fractions (Fig. 1A). Two fractions (eluted at 8-9 and 
10-11 ml) were judged to contain [125I]hGH:receptor com-
plexes since [125I]hGH was absent when the solubilized recep-
tors were pre-incubated with [125I]hGH in the presence of 
excess unlabeled hGH. The two other peaks of radioactivity 
(eluted at 13 and 15 ml) represented dimers and monomers of 
free [125I]hGH. In the second experiment, fractions eluted fol-
lowing gel filtration of the free receptors revealed two peaks of 
activity, eluted respectively at 7-8 and 10.5-11.5 ml (Fig. IB). 
Their respective molecular masses, as calculated from a stand-
ard curve (Fig. 1C), were 540-580 and 190-210 kDa. These 
fractions were subsequently cross-linked to [125I]hGH and an-
alyzed by SDS-PAGE (4-10% gradient) followed by autora-
diography. Several specifically labeled bands were detected 
within the range of 84-200 kDa (not shown). There was, 
however, no difference between the two peaks of activity, in-
dicating the higher molecular-mass fraction to be an oligomer 
of essentially similar components which likely underwent par-
tial proteolysis during the preparation of the solubilized mi-
crosomal fraction. 
3.2. Determination of the stoichiometry of PRLR.oPL 
complex in intact Nb2-llC cells by affinity labeling 
Since the experiments described in the former paragraph 
were not conclusive enough to ensure existence of lactogen 
hormone-induced receptor dimerization this set of experi-
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Fig. 1. Superose 12 column chromatography of [125I]hGH:PRL-R 
complexes (A) or free receptors in the solubilized microsomal frac-
tion (B). Complex formation (A) was performed in the absence 
( ) or in presence (• • •) of excess hGH and the tubes, collected 
during the chromatography, were counted in a y-counter. The free 
receptor eluted from the column (B) was detected by determination 
of its ability for specific [125I]hGH binding. A standard curve (C) 
was determined with the following markers: thyroglobulin (669 
kDa), apoferritin (443 kDa), p-amylase (200 kDa), alcohol dehydro-
genase (150 kDa) and bovine serum albumin (66 kDa). 
ments was performed in intact cells. Preparation of recombi-
nant oPL [11] and our findings that its complex with rPRLR-
ECD are more stable than those formed by hGH prompted us 
to chose it as a ligand [7,9]. Using autoradiography (Fig. 2), 
two specific bands with molecular masses of 82 and 141 kDa 
were identified; scanning of the autoradiograph revealed an 
approximate 3:1 ratio. These bands most probably corre-
spond to 1:1 and 2:1 hormone/receptor complexes, having 
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Fig. 2. Affinity labeling of PRLR in intact Nb2 cells. The cross-
linked [125I]oPL:PRLR complexes from intact Nb 2 - l lC cells pre-
pared in the absence (lane 1) or presence (lane 2) of 40 ug oPL 
were subjected to tricine-SDS-PAGE (7.5%) in the presence of re-
ducing agent. The gel was then fixed, dried, autoradiographed and 
scanned. 
The gel-filtration experiments (Fig. 3) indicated that the 
receptor existing in the solubilized microsomal fraction aggre-
gates into large molecular forms. The apparent molecular 
mass of the lowest of these (190-210 kDa), corrected for the 
presence of Triton X-100 [16] was 133-147 kDa, close to that 
obtained by affinity labeling. SDS-PAGE analysis in the pres-
ence of reducing agent indicated it to be composed of several 
species suggesting the occurrence of partial proteolysis during 
preparation of the microsomal fraction. Since the higher mo-
lecular form (540-580 kDa) showed a similar profile when 
analyzed by SDS-PAGE, it most likely represents a receptor 
oligomer. It should be noted that formation of these aggre-
gates was not induced by hormone binding, and that almost 
the same molecular species were yielded by gel filtration of the 
PRLR-hGH complexes and the free receptor (Fig. 3). One 
possible explanation of this finding is that in situ, the recep-
tors already exist as dimers or oligomers, and hormone-in-
duced dimerization in fact stabilizes the complex or changes 
its conformation. This suggestion must however be treated 
with caution since difficulties concerned with the preparation 
of the soluble microsomal fraction, such as absolute preven-
tion of partial proteolysis and the use of detergent may lead to 
an artificial appearance of oligomeric proteins under non-de-
naturing conditions. The results obtained with the intact cells 
are more conclusive to show formation of 2:1 receptor/hor-
mone complex. It implies that the hormone-induced receptor 
dimerization or hormone-induced structural transition of a 
pre-existing receptor dimer that allows transphosphorylation 
of the PRLR-associated JAK2 kinases is an initial event in the 
transduction of the biological signal [17,18]. Although experi-
ments performed by us [7,9,11] or others [1,2] with soluble 
recombinant PRLR- or GHR-ECDs and the indirect kinetic 
theoretical masses of 87 and 152 kDa, respectively. The spe-
cificity of the binding is further demonstrated in Fig. 2, which 
shows the binding of [125I]oPL to be fully displaced by the 
lactogenic hormones such as oPL, hGH and oPRL, but not 
by the somatogenic oGH. An additional specific band with a 
molecular mass of 21-25 kDa most likely represents free li-
gand that was non-covalently associated with the receptor and 
dissociated due to the SDS treatment. 
4. Discussion 
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The affinity labeling experiments suggest that PRLR an-
chored in the membrane of intact M>2 cells undergoes lacto-
genic hormone-induced dimerization and support our recent 
findings which showed that rPRLR-ECD is capable to form 
2:1 complex with lactogenic hormones [7,11] although the 
complex undergoes fast dissociation to a 1:1 form [9]. The 
finding that the homodimeric complex formed with oPL or 
bPL is more stable than that formed with hGH may explain 
why in previous experiments [15], only 1:1 complex could be 
detected. Our kinetics analysis [9] is consistent with this find-
ing, in that it showed that the kon kinetics constants character-
izing the association of the rat PRLR-ECD to oPL sites 1 and 
2 are almost identical, whereas the kQf{ values for site 2 were 
12-fold those of site 1. This also explains why the relative 
amount of the 2:1 complex is much lower than that of the 
1:1 complex (Figs. 1 and 2). 
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Fig. 3. Affinity labeling of PRLR intact Nb2 cells. The cross-linked 
[125I]oPL:PRLR complexes from intact Nb2-llC cells prepared in 
the absence (lane 1) or presence of 40 (Xg oPL, hGH, oPRL or 
oGH (lanes 2-5, respectively). For other details, see Fig. 1. 
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experiments [3,10] favor the hormone-induced receptor dimer-
ization model the other possibility cannot be yet excluded. 
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